Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer

Clinical Cancer Research

Volumn 2, Issue 10, 1996, Pages 1767-1775

  Trivers, Glenwood E ^a   De Benedetti, Virna M G ^a,c   Cawley, Helen L ^a   Caron, Gail ^b   Harrington, Anita M ^a   Bennett, William P ^a   Jett, James R ^b   Colby, Thomas V ^b   Tazelaar, Henry ^b   Pairolero, Peter ^b   Miller, Roland D ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, NEOPLASM; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PRECIPITIN TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10244219862     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Crawford, L. V., Pim, D. C., and Bulbrook, R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer, 30: 403-408, 1982.
2. Davidoff, A. M., Iglehart, J. D., and Marks, J. R. Immune response to p53 is dependent upon p53/HS70 complexes in breast cancer. Proc. Acad. Sci. USA, 89: 3439-42, 1992.
3. Green, J A., Mudenda, B., Jenkins, J., Leinster, S. J., Tarunina, M., Green, B., and Robertson, L. Serum p53 auto-antibodies: incidence in familial breast cancer. Eur. J. Cancer, 30A: 580-584, 1994.
4. Peyrat, J-P., Bonneterre, J., Lubin, R., Van Lemmens, L., Vaniemmens, L., Fournier, J., and Soussi, T. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. The Lancet, 345: 621-622, 1995.
5. Winter, S. F., Minna, J. D., Johnson, B. E., Takahashi, T., Gazdar, A. F., and Carbon, D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent upon the type of p53 mutation. Cancer Res., 53: 4168-4174, 1992.
6. Schlichtholtz, B., Tredamel, J., Lubin, R., Zalcman, G., Hirsch, H., and Soussi, T. Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer, 69: 809-816, 1994.
7. Guinee, D. G., Jr., Trivis, W. D., Trivers, G. E., DeBenedetti, V. M. G., Cawley, H., Welsh, J , Bennett, W., Jett, J., Colgy, T. V., and Tazelaar, S. L. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and c-erg-2 expression. Carcinogenesis (Lond.), 16: 993-1002, 1995.
8. Volkmann, M., Muller, M., Hoffmann, W. J., Meyer, M., Hagelstein, J., Rath, U., Kommerell, B., Zentgraf, H., and Galle, P. R. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and dependent of the α-fetoprotein status. Hematology, 18. 559-565, 1993.
9. Trivers, G. E., Cawley, H. L., DeBenedetti, V. M. G., Hollstein, M., Marion, M. J., Bennett, W. P., Hoover, M. L., Prives, C., Tamburro, C., and Harris, C. C. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J. Natl. Cancer Inst., 87: 1400-1407, 1995.
10. Preudhomme, C., Lubin, R., Lepeppey, P., Vsnrumbeke, M., and Fenaux, P. Detection of serum anti p53 antibodies and their connection with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia (Baltimore), 8: 1589-1591, 1994.
11. Caron de Fromentel, C., May-Levin, F., Mouriesse, H., Lemerle, J., Chandrasekaran, K., and May, P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39: 185-189, 1987.
12. Sjorern, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88: 173-182, 1996.
13. Mitsudomi, T., Oyama, T., Kusano, T., Osaki, T., Nakanishi, R., and Shirakusa, T. Mutations of the p53 gene as predictor of poor prognosis in patients with non-small cell lung cancer. J. Natl. Cancer Inst., 85: 2018-2023, 1993.
14. Iwaya, K., Tsuda, H., Hiraide, H., Tamiki, K., Tamakuma, S., Fukutomi, T., Mukai, K., and Hirohaski, S. Nuclear p53 immunoreaclion associated with poor prognosis of breast cancer. Jpn. J. Cancer Res., 82: 835-840, 1991.
15. Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L. C., Mayall, B. H., and Smith, H. S. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst, 84: 845-855, 1992.
16. Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., and Doshi, H. M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52: 4828-4831, 1992.
17. Bauer, J. J., Sesterhenn, I. A., Mostofi, K. F., Mcleod, D. G., Srivastava, S., and Moul, J. W. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res., 1: 1295-1300, 1995.
18. Winter, S. F., Sekido, Y., Minna, J. D., McIntire, D., Johnson, B. E., Gazdar, A. F., and Carbone, D. P. Antibodies against autologous tumor cell proteins in patients with small cell lung cancer: association with improved survival. J. Natl. Cancer Inst., 85: 2012-2018, 1993.
19. Lubin, R., Zalcman, G., Bouchet, L., Tredaniel, J., Legros, Y., Cazals, D., Hirsch, A., and Soussi, T. Serum p53 antibodies as early markers of lung cancer. Nat. Med., 1: 701-702, 1995.
20. Buist, S. A., Connett, J. E., Miller, R. D., Kanner, R. E., Owens, G. R., and Voelker, H. T. Chronic obstructive pulmonary disease early intervention trial (Lung Health Study): baseline characteristics of randomized participants. Chest, 103: 1863-1872, 1993.
21. 1. J. Am. Med. Assoc., 272: 1497-1505, 1994.
22. Wang, E. H., Friedman, P. N., and Prives, C. The murine p53 protein blocks replication in vitro by binding the initiation functions of SV40 large T antigen. Cell, 57: 379-392, 1989.
23. Fnedman, P. N., Kern, S. E., Vogelstein, V., and Prives, C. Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. Proc. Natl. Acad. Sci. USA, 87: 9275-9279, 1990.
24. Garfin, D. E., Immunoblotting. In: N. R. Rose, E. C. de Macario, J. L. Fahey, H. Friedman, and G. M. Penn (eds.), Manual of Clinical Laboratory Immunology, pp. 47-51. Washington, DC: American Society for Microbiology, 1992.
25. O'Reilly, D., and Miller, L. Expression and complex formation of simian virus 40 large T antigen and mouse p53 in insect cells. J. Virol., 62: 3109-3119, 1988.
26. Felly-Bosco, E., Weston, A., Cawley, H., Bennett, W. P., and Harris, C. C. Functional studies of a germ-line polymorphism at codon 47 within the p55 gene. Am. J. Hum. Genet., 53: 752-759, 1993.
27. DeBenedetti, V. M. G., Travis, L. B., Welsh, J. A., van Leeuwen, F. E., Stovall, M., Clarke, E. A., Boice, J. D., Jr., and Bennett, W. P. p53 mutations in lung cancer following radiation therapy for Hodgkin's disease. Cancer Epidemiol., Biomarkers & Prev., 5: 93-98, 1996.
28. Ramet, M., Castren, K., Jarvinen, K., Pekkala, P , Turpeenniemi-Hujanen, T., Soini, Y., Paakko, P., and Vahakangas, K. p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis (Lond.), 10: 2117-2124, 1993.
29. Vojtesek, B , Kovarik, J. U., Dolezalova, H., Nenutil, R., Havlis, P., Brentani, R. R., and Lane, D. Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br. J. Cancer, 71: 1253-1256, 1995.
30. Wild, C. P., Ridanpää, M., Anttila, S., Lubin, R., Soussi, T., Husgafvel-Pursiainen, K., and Vainio, H. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumor tissue. Int. J. Cancer (Pred. Oncol.), 64: 176-181, 1995.
31. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
32. Hamelin, R., Flejoou, J. F., Muzeau, F. Potet, F., Laurent-Puig, P., Fekete, F., and Thomas, G. TP gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology, 107: 1012-1018, 1994.
33. Symmans, P. J., Linehan, J. M , Brito, M. J., and Filipe, A. I. p53 expression in Garrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J. Pathol., 173: 221-226, 1994.
34. Bennett, W., Hollstein, M., Metcalf. R. A., Welsh, J., He, A., Si-min, Z., Kusters, I., Resau, J. H., Thrump, B. J., Lane, D. P., and Harris, C. C. p53 mutations and protein accumulation during multistage human esophageal carcinoma. Cancer Res., 53: 6092-6097, 1992.
35. Vahakangas, K., Samet, J. M., Metcalf, R. A., Welsh, J. A., Bennett, W. P., Lane, D., P., and Harris, C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet, 339: 576-580, 1992.
36. Sozzi, G., Miozzo, M., Donghi, R., Pilotti, S., Cariani, C. T., Pastorino, U., Della Porta, G., and Perotti, M. A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res., 52: 6079-6082, 1992.
37. Sundaresan, V., Ganly, P., Hasleton, P., Rudd, R., Sinha, G., Bleehen, N. M., and Raggitts, P. p53 and chromosome 3 abnormalities: characteristic of malignant lung tumors are detectable in preinvasive lesions of the bronchus. Oncogene, 7: 1989-1997, 1992.
38. Ziegler, A., Jonason, A. S., Leffell, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., and Brash, D. E. Sunburn and p53 in the onset of skin cancer. Nature (Lond.) 372: 773-776, 1994.